, Volume 23, Issue 4, pp 195-198
Date: 05 Feb 2009

ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI)

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

John Overington holds a first degree in chemistry, and studied for his PhD on comparative protein modeling, drug design, and sequence-structure relationships with Sir Tom Blundell FRS, at Birkbeck College, London. After a postdoctoral fellowship with the Imperial Cancer Research Fund, London, he joined Pfizer Central Research in the UK and eventually became manager of the Molecular Informatics, Structure and Design Department, where he was responsible for cheminformatics, structural biology, target analysis, and molecular modeling. He joined Inpharmatica in 2000; Inpharmatica was acquired by Galapagos NV in December 2006. There he was Senior Director, Discovery Informatics of the Galapagos subsidiary BioFocus DPI. In October 2008 he was appointed Team Leader, Chemogenomics at the European Molecular Biology Laboratory (EMBL), working at the European Bioinformatics Institute (EMBL-EBI) in Hinxton, UK. His ChEMBL group’s research focuses on mapping the interactions and functional effects ...